enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Donanemab - Wikipedia

    en.wikipedia.org/wiki/Donanemab

    Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.

  3. FDA approves donanemab, Eli Lilly’s treatment for early ...

    www.aol.com/fda-approves-donanemab-eli-lilly...

    The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.

  4. FDA approves Alzheimer’s treatment that has been shown to ...

    www.aol.com/news/fda-approves-alzheimer...

    The FDA approved a new Alzheimer’s drug that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities. ... The drug donanemab, which will be sold under the ...

  5. In an unusual move, FDA postpones approval decision for Lilly ...

    www.aol.com/news/unusual-move-fda-postpones...

    The Food and Drug Administration has pushed back its approval decision deadline for Eli Lilly’s experimental Alzheimer’s drug donanemab. Lilly applied to the FDA for approval of the drug in ...

  6. Anti-amyloid drugs - Wikipedia

    en.wikipedia.org/wiki/Anti-amyloid_drugs

    Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [31] [32] Donanemab was developed by Eli Lilly and Company. [33] [34] The most common side effects include amyloid-related imaging abnormalities and headache. [32] Donanemab was approved for medical use in the United States in ...

  7. Eli Lilly Alzheimer's drug to be blocked for use by NHS, The ...

    www.aol.com/news/eli-lilly-alzheimers-drug...

    A decision on donanemab has been delayed, with the regulatory agency initially planning to make a call in July, the same time it was approved for use in the U.S., the report said.

  8. Donanemab – what we know about the latest Alzheimer’s drug

    www.aol.com/donanemab-know-latest-alzheimer-drug...

    Donanemab can slow the progression of Alzheimer’s disease. ... Before the new treatment is approved for widespread use in the health service it needs a green light from the National Institute ...

  9. Gantenerumab - Wikipedia

    en.wikipedia.org/wiki/Gantenerumab

    Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals. [1] [2]Gantenerumab binds to and clears aggregated beta amyloid fibers.